6-氯-2-萘磺酸 | 102878-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6-氯-2-萘磺酸
• 英文名称: 6-chloro-2-naphthalenesulphonic acid
• 英文别名: 6-chloro-naphthalene-2-sulfonic acid；6-Chlor-naphthalin-2-sulfonsaeure；6-chloro-2-naphthalenesulfonic acid；6-chloronaphthalene-2-sulfonic acid
• CAS: 102878-14-8
• 化学式: C₁₀H₇ClO₃S
• 分子量: 242.683
• InChiKey: ONLHWRHIJDODKO-UHFFFAOYSA-N

物化性质

• 密度：
  1.533±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2904909090

反应信息

• 作为反应物：
  描述：

  6-氯-2-萘磺酸 在 氯化亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-tert-Butoxycarbonyl-4-((6-chloronaphthalen-2-yl)sulfonyl]-2-ethoxycarbonylpiperazine
  参考文献：
  名称：

  Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine derivatives

  摘要：

  In our investigation of factor Xa inhibitors, a series of 1-(6-chloronaphthalen-2-yl)sulfonyl-4-(4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carbonyl)piperazines 3a-i were synthesized. In vitro inhibitory activities of the compounds against factor Xa and coagulation are summarized. Among the compounds, 3c and 3d, possessing a carbamoyl or N-methylcarbamoyl moiety, showed potent inhibitory activities when administered orally to rats. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.036
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 6-氯-2-萘磺酸
  参考文献：
  名称：

  Armstrong, Chemical news and journal of industrial science, 1888, vol. 58, p. 295

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS<br/>[FR] SULFONAMIDES SUBSTITUÉS UTILES COMME INHIBITEURS DE BCL ANTI-APOPTOTIQUES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2012162365A1

  公开（公告）日：2012-11-29

  Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.

  揭示了式（I）的化合物或其药学上可接受的盐，其中：W、Q和G在此处被定义。还揭示了将这些化合物用作Bcl-2家族抗凋亡蛋白的抑制剂以治疗癌症的方法；以及包含这些化合物的药物组合物。
• Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
  申请人：——

  公开号：US20040006062A1

  公开（公告）日：2004-01-08

  The present application describes sulfonylaminovalerolactams and derivatives thereof of Formula I: 1 or pharmaceutically acceptable salt forms thereof, wherein ring G is a mono- or bicyclic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.

  本申请描述了Formula I中的磺酰氨基戊内内酰胺及其衍生物，或其药用盐形式，其中环G是单环或双环碳环或杂环。本发明的化合物可用作胰蛋白酶样丝氨酸蛋白酶抑制剂，特别是对凝血因子Xa的抑制剂。
• Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents
  申请人：ZENECA LIMITED

  公开号：US20030207882A1

  公开（公告）日：2003-11-06

  Compounds of formula (I), wherein G 1 is CH or N; G 2 is CH or N; R 1 is a variety of optional substituents, L 1 is (1-4C)alkylene; T 1 is CH or N; R 2 and R 3 are independently hydrogen or (1-4C)alkyl or are joined to form a ring; X 1 and X 2 represent various linking groups; Ar is phenylene or certain heteroaryl rings and Q represents a variety of aromatic or heterocyclic rings systems, and pharmaceutically acceptable salts thereof are described as useful antithrombotic and anticoagulant agents, and are selective Factor Xa inhibitors. Processes for their preparation and pharmaceutical compositions containing them are also described. 1

  式（I）的化合物，其中G1为CH或N；G2为CH或N；R1为各种可选取代基，L1为（1-4C）烷基；T1为CH或N；R2和R3独立地为氢或（1-4C）烷基或连接成环；X1和X2代表各种连接基团；Ar为苯基或特定杂环芳基，Q代表各种芳香或杂环芳基系统，及其药学上可接受的盐被描述为有用的抗血栓和抗凝血剂，并且是选择性的凝血因子Xa抑制剂。还描述了其制备方法和含有它们的药物组合物。
• Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
  申请人：——

  公开号：US20020183324A1

  公开（公告）日：2002-12-05

  The present application describes monocyclic or bicyclic carbocycles and heterocycles and derivatives thereof of Formula I: 1 or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.

  本申请描述了单环或双环碳环和杂环以及其衍生物的化合物I的公式，或其药用可接受的盐形式，这些化合物对于Xa因子的抑制剂具有用处。
• Heterocyclic amides as inhibitors of factor Xa
  申请人：Eli Lilly and Company

  公开号：US06660739B1

  公开（公告）日：2003-12-09

  This application relates to a compound of formula I (or a pharmaceutically acceptable salt thereof) as defined herein, pharmaceutical compositions thereof, and its use as an inhibitor of factor Xa, as well as a process for its preparation and intermediates therefor.

  本申请涉及公式I的化合物（或其药用可接受的盐），其药物组合物，以及其作为Xa因子抑制剂的用途，以及其制备过程和中间体。